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Abstract
Background The prevalence of dyslipidaemia and the risk of cardiovascular
disease are elevated in patients with type 2 diabetes. This analysis compared
the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid
proﬁles.
Methods Patient-level data were pooled from two randomized clinical studies.
The population included 552 men and women aged >18 years, diagnosed with
type 2 diabetes for at least 6 months, on metformin and/or sulphonylurea, and
with A1C ≥7.5% and <12.0% at screening. Lipid outcome measures included
change from baseline in lipid levels [low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density
lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, and
free fatty acids] and attainment of lipid goals for LDL-C, non-HDL-C, and
triglycerides.
Results Both insulin glargine and TZDs improved lipid proﬁles from baseline
values. Compared with TZDs, treatment with insulin glargine led to 7.9%
greater reduction in LDL-C (p<0.0003), 7.5% greater reduction in non-HDL-C
(p<0.0001), and 7.8% greater reduction in total cholesterol (p<0.0001),
whereas the HDL-C increase with TZD was 7.6% greater than that with insulin
glargine (p<0.0001). The percentage of patients attaining the lipid goals
was comparable between insulin glargine and pioglitazone, but lower for
rosiglitazone. Insulin glargine improved glycaemic control more than TZDs;
however, insulin glargine caused more hypoglycaemia. Treatment with TZDs
caused more weight gain and peripheral oedema.
Conclusion These ﬁndings suggest that the favourable effects of insulin
glargine on plasma lipid proﬁles should be considered among the advantages
of treatment with insulin glargine as they are for TZDs. Copyright © 2011 John
Wiley & Sons, Ltd.
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Introduction
It is well established that the prevalence of dyslipidaemia and the risk of
cardiovascular disease (CVD) are greater in patients with type 2 diabetes than
in the general population [1–4]. Elevated plasma lipid concentrations are well-
recognized risk factors for CVD, and reducing them to the values recommended
by the American Diabetes Association (ADA) and the American Heart
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in individuals with type 2 diabetes [1,5–7]. Thus, the
effect of antihyperglycaemic therapies on lipid para-
meters merits consideration in the treatment of type 2
diabetes patients.
Over the years, insulin was suspected to be atherogenic
[8–10], whereas thiazolidinediones (TZDs) were consid-
ered to have cardioprotective potential [11,12]. These
properties have been regarded to contribute to the
unfavourable effects of insulin and beneﬁcial effects of
TZDs on lipids [13,14]. However, clinical studies indicate
that insulin therapy produces favourable effects on
plasma lipid concentrations in patients with type 2
diabetes [15–18]. In particular, treatment with insulin
glargine has been associated with improvement in
the levels of low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C), non-high-
density lipoprotein cholesterol (non-HDL-C), total choles-
terol (TC), and triglycerides (TGs) [15,16,18]. Therefore,
to investigate in greater detail the comparative effects of
insulin glargine, rosiglitazone, and pioglitazone on lipo-
protein and glycaemic parameters, we identiﬁed two ran-
domized clinical studies that compared insulin glargine
with a TZD in the treatment of type 2 diabetes [19,20].
Although these studies were designed primarily to evalu-
ate glycaemic control, lipoprotein levels were also deter-
mined [19,20]. One study compared insulin glargine with
rosiglitazone [19], and another study compared insulin
glargine with pioglitazone [20]. The pooled analysis
suggests that insulin glargine has positive effects on
several lipoprotein parameters often seen elevated in this
population, and conﬁrms the known effects of TZDs on
lipids [19,20].
Materials and methods
Participant-level data were pooled from two previously
published randomized studies comparing the efﬁcacy,
safety, and tolerability of insulin glargine versus a TZD,
either pioglitazone or rosiglitazone, in type 2 diabetes.
These studies [19,20] were selected for analysis because
they had similar patient proﬁles, included thorough mea-
surement of lipid parameters, and compared the effects of
insulin glargine with one of the twoTZDs available at the
time of the study. Each study used a randomized, parallel-
group, two-arm, open-label design with outcome mea-
surements after 24 weeks of treatment. The participants
included men and women aged >18 years, diagnosed
with type 2 diabetes for at least 6months, on metformin
and/or sulphonylurea, and with A1C ≥7.5% and <12.0%
at screening.
The participants in the analysis were randomized
patients who had baseline measurements, received at
least one dose of study medication, and had outcome
measurements from at least one follow-up visit. Patient-
level data from the 552 participants who met these
criteria were included in the pooled analysis.
Treatments
Patients were randomized to insulin glargine titrated to a
fasting plasma glucose (FPG) goal of <5.55 mmol/L
(<100 mg/dL) or to a TZD comparator level (pioglitazone
or rosiglitazone) [19,20]. Detailed information regarding
treatment procedure is available in prior publications
[19,20]. Study protocols were approved by the respective
independent review boards, and both studies were con-
ducted in accordance with the principles of the Declara-
tion of Helsinki. Written informed consent was obtained
from study participants prior to any treatment initiation.
Because of the design of the individual studies, all
patients randomized to rosiglitazone also were taking
both metformin and a sulphonylurea [19], and all patients
receiving pioglitazone were taking either metformin or a
sulphonylurea [20]. For patients who were taking a
lipid-lowering medication (e.g. statin or ﬁbrate) at study
onset, titration of these medications was permitted under
the protocol at the discretion of the treating physician.
Outcome measures
The lipid outcome measures for this post hoc analysis
were (1) change from baseline in plasma lipid levels:
LDL-C, HDL-C, non-HDL-C, TC, TGs, and free fatty acids
(FFAs); (2) attainment of ADA/AHA recommended goals
for LDL-C [<2.59 mmol/L (<100 mg/dL)], non-HDL-C
[<3.37 mmol/L (<130 mg/dL)], and TGs [<1.70mmol/L
(<150 mg/dL)]; and (3) attainment of TC/HDL-C <4.5
and LDL-C/HDL-C <3.5. Glycaemic control was measured
by change from baseline in A1C and FPG and proportion
of patients achieving A1C ≤7.0%. The safety evaluation
included body weight, peripheral oedema, and episodes of
symptomatic and severe hypoglycaemia.
Fasting blood samples were collected at baseline and
weeks 6, 12, 18, and 24 and were sent for analysis to a
central laboratory thatparticipated in the Lipid Standardiza-
tion Program of the Centers for Disease Control (Covance
Central Laboratory Services, Indianapolis, IN). The TC and
TG assays were performed using Hitachi analyzers (Hitachi,
Ltd, Japan). Direct HDL-C was measured with an enzymatic
colorimetric assay (Roche Diagnostics, Indianapolis, IN).
Low-density lipoprotein cholesterol was calculated using
the Friedewald formula (TCHDL-CTG/5) [21]. FFAs
were measured using the Wako enzymatic non-esteriﬁed
(free) fatty acids (NEFA) method. The A1C assay was
performed on a Bio-Rad Variant
™ Analyzer (Bio-Rad
Laboratories, Hercules, CA).
Statistical analysis
Analysis of covariance (ANCOVA) was used to evaluate
change from baseline for lipid outcomes, glycaemic out-
comes, and weight. Each ANCOVA model included
treatment (insulin glargine versus pooled TZD) and study
as ﬁxed effects and corresponding baseline level as a
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tions, additional ANCOVAs were conducted for change
from baseline in each lipid outcome, with treatment
(insulin glargine versus pooled TZD) and statin/ﬁbrate
use (yes versus no) as ﬁxed effects and lipid baseline level
as covariate. Lipid parameters were analysed on a log
scale, to adjust for non-normal distributions, and then
back-transformed for reporting results. If measurement
of an outcome variable was not available at week 24, then
the last observation post-baseline was carried forward.
Continuous lipid values measured at baseline were
categorized into quartiles. Analysis of variance of change
from baseline was conducted for each lipid outcome vari-
able, with treatment and baseline quartile as factors. To
compare the effects of the three treatments (insulin glar-
gine, pioglitazone, and rosiglitazone), paired comparisons
on the change from baseline lipid concentration were
performed using t-tests.
Stepwise linear regression models were used to identify
additional factors that may have contributed signiﬁcantly
to lipid outcomes in this analysis. For each lipid parame-
ter, 26 potential covariates were available for selection:
age, sex, race, body mass index (BMI), duration of
diabetes, treatment (insulin glargine or TZD), study
(Rosenstock or Meneghini), concomitant statin/ﬁbrate
use, concomitant use of blood pressure medication, back-
ground use of sulphonylurea, background use of metformin,
background use of metformin and sulphonylurea, baseline
A1C, baseline FPG, baseline weight, baseline systolic blood
pressure, baseline diastolic blood pressure, baseline heart
rate, baseline TC, baseline LDL-C, baseline HDL-C, baseline
TGs, baseline FFA, change in FPG from baseline, change in
A1C from baseline, and change in weight from baseline. A
signiﬁcance level of p≤0.15 was required for a covariate
to enter into the model and p≤0.10 to be retained in the
ﬁnal model.
Results
Table 1 shows the demographic and baseline characteris-
tics of the 552 patients included in the pooled analysis. A
total of 264 patients were randomized to insulin glargine
and 288 patients to TZD (112 to rosiglitazone and 176 to
pioglitazone). Not all patients had complete lipid data, so
analyses of most lipid outcomes included 258 patients
treated with insulin glargine and 278 with TZD (110
rosiglitazone and 168 pioglitazone). Low-density lipoprotein
cholesterol values were not calculated for 54 participants
(24 insulin glargine, 9 rosiglitazone, 21 pioglitazone) with
TGs >4.52 mmol/L (>400 mg/dL) because LDL-C calcula-
tion becomes unreliable under such conditions [21].
Changes in plasma lipid levels
Changes in lipid parameters are shown in Table 2; ad-
justed values were controlled for study differences and
Table 1. Demographic and baseline characteristics
Insulin glargine (n=264) All TZDs (n=288)
Age (years) 54.210.9 53.310.7
Female, n (%) 134 (50.8) 134 (46.5)
Race, n (%)
White 171 (64.8) 199 (69.1)
Black 51 (19.3) 44 (15.3)
Hispanic 32 (12.1) 39 (13.5)
Other 10 (3.8) 6 (2.1)
Duration of diabetes (years) 7.35.5 6.84.7
Lipid-reducing therapy, statin or ﬁbrate, n (%) 103 (39.0) 107 (37.2)
Background oral anti-diabetic drug therapy, n (%)
Metformin
a 90 (34.1) 103 (35.8)
Sulphonylurea
a 69 (26.1) 73 (25.3)
Metformin+sulphonylurea
a 105 (39.8) 112 (38.9)
Weight (kg) 96.820.5 97.921.1
BMI (kg/m
2) 34.17.8 33.76.6
Lipid values, meanSE (mg/dL)
b
LDL-C 109.22.12 106.72.21
HDL-C 42.31.46 41.51.44
Non-HDL-C 151.21.74 150.51.69
Total cholesterol 195.61.39 194.21.33
Triglycerides 194.34.18 198.83.63
Free fatty acids 52.92.72 51.22.50
Glycaemic values
A1C (%) 9.11.1 9.11.2
FPG (mg/dL) 209.163.3 209.161.3
c
Data are meanSD, except where indicated.
BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol; TZD, thiazolidinedione.
aBecause of differences in study design, all 176 TZD patients taking either metformin or a sulphonylurea were treated with pioglitazone,
and all 112 TZD patients taking metformin and a sulphonylurea were treated with rosiglitazone.
bLipid levels reported as geometric means.
cn=287.
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ences between the effects of insulin glargine and pooled
TZD on the levels of LDL-C (p=0.0003), non-HDL-C
(p<0.0001), and TC (p<0.0001); insulin glargine
treatment reduced whereas pooled TZD treatment
increased these cholesterol levels. Insulin glargine
therapy had favourable effects on TGs and FFAs, but the
differences were of borderline statistical signiﬁcance. For
example, treatment with insulin glargine resulted in a
44.5% greater reduction in TGs compared with pooled
TZD treatment [0.21 versus 0.14mmol/L (18.5 versus
12.8 mg/dL), respectively; p=0.0504]. High-density
lipoprotein cholesterol levels increased signiﬁcantly more
with pooled TZD than with insulin glargine therapy
(p<0.0001).
In spite of elevated LDL-C, non-HDL-C, and TG levels at
baseline, 61.4% of participants in the analysis were not
taking lipid-lowering medications. Among these patients,
7.5% in the insulin glargine group and 5.3% in the TZD
group were started on statin/ﬁbrate therapy during the
study. When patients’ use of statin/ﬁbrate medication
was controlled, the differences for insulin glargine versus
pooled TZD treatment were unchanged. This analysis also
evaluated the lipid effects of insulin glargine and pooled
TZD treatment separately for patients who were taking a
statin or ﬁbrate and those who were not (Table 3). Insulin
glargine produced greater improvement in LDL-C, non-
HDL-C, TC, TGs, and HDL-C in patients already taking a
lipid-lowering medication compared with those who were
not. For the pooled TZD group, an increase in LDL-C was
greater in patients taking a lipid-lowering medication,
whereas an increase in TC was greater in patients receiv-
ing no lipid-lowering treatment. TZD-related improve-
ment in HDL-C and TGs was greater in patients taking a
lipid-lowering medication, whereas improvement in FFAs
was greater in those not taking the medication.
Attainment of the recommended lipid goals was
assessed at the end of treatment for LDL-C, non-HDL-C,
and TGs. Compared with TZDs, insulin glargine treatment
enabled more patients to reach the goals for LDL-C (32.7
versus 37.2%), non-HDL-C (29.1 versus 38.8%), and TGs
(43.5 versus 49.6%). Patients treated with insulin glargine
or pioglitazone generally showed comparable goal attain-
ment, but fewer patients taking rosiglitazone reached the
lipid goals. For example,19% more patients taking insulin
glargine than those taking rosiglitazone reached the goals
for non-HDL-C and TGs. Compared with insulin glargine,
pioglitazone enabled more patients to attain the goals for
LDL-C/HDL-C <3.5 (91.5 versus 87.3%) and TC/HDL-C
<4.5 (66.1 versus 55.0%). Overall, however, lipid goal
attainment remained suboptimal in most patients.
Baseline lipid measurements were categorized into
quartiles to determine whether the changes observed
in lipid parameters varied by baseline concentration.
Changes from baseline were analysed by baseline quartile
and treatment (insulin glargine, rosiglitazone, or pioglita-
zone) for each lipid parameter (Figure 1). Improvement in
lipid levels differed signiﬁcantly depending on baseline
concentration (p<0.0001 for LDL-C, non-HDL-C, TC,
TGs, and FFAs; p=0.0252 for HDL-C), with the greatest
improvement generally observed among patients who
had the most abnormal lipid concentrations at baseline.
For example, treatment with insulin glargine or pioglitazone
produced an average decrease in LDL-C of more than
20mg/dL among patients in the highest quartile at baseline;
however, patients in the lower two quartiles experienced a
modest increase. Signiﬁcant treatment differences were
obtained for LDL-C (p<0.0001), HDL-C (p<0.0001),
Table 2. Changes from baseline in lipid levels, pooled analysis
Unadjusted Adjusted
a
Baseline
b Endpoint
b
Change from
baseline (%)
Change from
baseline (%)
Difference in change
from baseline (%) p value
LDL-C (mg/dL)
Insulin glargine 109.212.1 105.922.1 3.011.7 1.9 7.9 0.0003
TZD 106.672.2 113.472.0 6.372.0 6.6
HDL-C (mg/dL)
Insulin glargine 42.291.5 42.981.6 1.630.9 1.1 7.6 <0.0001
TZD 41.461.4 45.831.5 10.521.2 9.4
Non-HDL-C (mg/dL)
Insulin glargine 151.201.7 140.921.7 6.801.3 5.9 7.5 <0.0001
TZD 150.501.7 151.741.8 0.821.6 1.7
Total cholesterol (mg/dL)
Insulin glargine 195.581.4 186.201.3 4.801.0 4.2 7.8 <0.0001
TZD 194.241.3 201.101.3 3.531.3 4.0
Triglycerides (mg/dL)
Insulin glargine 194.274.2 156.224.0 19.592.8 18.5 6.5 0.0504
TZD 198.793.6 169.643.5 14.662.7 12.8
Free fatty acids (mg/dL)
Insulin glargine 52.922.7 38.323.0 27.593.5 25.8 7.3 0.0528
TZD 51.152.5 40.892.8 20.053.3 20.0
Data are meanSE.
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein
cholesterol; TZD, thiazolidinedione.
aAdjusted for study and baseline lipid concentration.
bGeometric means.
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(p=0.0298). Insulin glargine was better than rosiglitazone
in reducing LDL-C (p<0.0001), non-HDL-C (p<0.0001),
TC (p<0.0001), and TGs (p=0.0361). Pioglitazone
produced greater improvement than did rosiglitazone
in LDL-C (p<0.0001), HDL-C (p<0.0001), non-HDL-C
(p<0.0001), TC (p<0.0001), and TGs (p=0.0094).Insu-
lin glargine and pioglitazone produced comparable bene-
ﬁts, except for greater reduction inTC with insulin glargine
(p=0.0481) and greater improvement in HDL-C with
pioglitazone (p<0.0001). Overall, both insulin glargine
and pioglitazone had beneﬁcial effects on lipid concentra-
tions; however, rosiglitazone had deleterious effects on
LDL-C, non-HDL-C, and TC.
Using stepwise regression models, we examined vari-
ous factors (covariates) that could serve as predictors of
changes in lipid levels in this pooled analysis. The amount
of variability in lipid measures that was explained by each
covariate is presented in Table 4. Baseline lipid concentra-
tion explained the largest amount of variability for each
lipid parameter except HDL-C; however, no other covariate
accounted for more than 5% of the variability for any lipid
level. Differences between insulin glargine and pooled TZD
treatment were signiﬁcant predictors for LDL-C, HDL-C,
non-HDL-C, TC, and TGs. For each lipid parameter except
HDL-C, insulin glargine was associated with greater im-
provement in lipid outcomes. Baseline A1C, baseline weight,
change in A1C, and change in weight did not account for the
variability in any lipid parameter except FFA.
Changes in glycaemic control
Bothinsulinglargine(adjustedmeanSEΔ=2.040.06%;
p<0.0001) and TZDs (adjusted meanSE 1.680.06%;
p<0.0001) reduced A1C, with insulin glargine produc-
ing a greater reduction in A1C than TZDs (meanSE
difference=0.360.09%; p<0.0001); however, the
difference was not signiﬁcant for patients with BMI
>35 kg/m
2. Both treatment groups also yielded signiﬁcant
reductions in FPG [insulin glargine: adjusted meanSE Δ=
4.510.16 mmol/L (81.332.9 mg/dL), p<0.0001;
TZD: adjusted meanSE Δ=3.210.16 mmol/L
(57.912.8 mg/dL), p<0.0001. Improvement in FPG
was signiﬁcantly greater with insulin glargine than with TZD
therapy [meanSE difference=1.300.22mmol/L
(23.423.9 mg/dL), p<0.0001], although the differ-
ence was not signiﬁcant for patients with BMI >40 kg/m
2.
Fifty percent of patients treated with insulin glargine and
42% of patients in the pooled TZD group achieved A1C
≤7.0% by the end of treatment.
Safety
Symptomatic hypoglycaemia [deﬁned as symptoms of
hypoglycaemia conﬁrmed by a blood glucose level of
<3.9 mmol/L (<70 mg/dL)] was reported by 32.6% of
patients treated with insulin glargine and 21.9% of
patients treated with a TZD. Severe hypoglycaemia
[deﬁned as symptomatic hypoglycaemia requiring third-
party assistance with a blood glucose level of <2.0 mmol/L
(<36 mg/dL) or recovery after oral carbohydrate, intrave-
nous glucose, or glucagon administration] occurred in
2.6% of insulin-glargine-treated and 2.4% of TZD-treated
patients. Treatment-related peripheral oedema was reported
in 6.6% of TZD-treated and 0% of insulin-glargine-treated
patients.
Weight increased in both the insulin glargine (adjusted
meanSE Δ=1.830.27 kg) and TZD (adjusted mean
SE Δ=2.980.26 kg) groups; however, TZD produced
signiﬁcantly greater weight gain (meanSE difference=
1.140.37 kg; p=0.0024, compared with glargine).
Table 3. Changes in lipid levels by statin/ﬁbrate use, pooled analysis
Insulin glargine versus pooled TZD
a Statin/ﬁbrate therapy No statin/ﬁbrate therapy
p value % Change % Change
LDL-C 0.0003
Insulin glargine 5.513.73 1.551.69
TZD 8.104.11 5.442.08
HDL-C <0.0001
Insulin glargine 2.761.37 0.901.11
TZD 11.671.51 9.841.68
Non-HDL-C <0.0001
Insulin glargine 9.072.62 5.291.33
TZD 0.973.24 1.931.67
Total cholesterol 0.0015
Insulin glargine 6.301.93 3.801.09
TZD 2.442.55 4.201.32
Triglycerides 0.0641
Insulin glargine 23.165.01 17.163.41
TZD 21.115.20 10.503.01
Free fatty acids 0.0547
Insulin glargine 27.085.50 27.934.54
TZD 18.055.99 21.233.89
Data are meanSE.
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein choles-
terol; TZD, thiazolidinedione.
aAdjusted for statin/ﬁbrate use and baseline lipid concentration.
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DOI: 10.1002/dmrrThere was a progressive increase in weight gain across
the BMI groups for TZD but not for insulin glargine.
The largest difference in weight gain was observed in
patients with BMI ≥40 kg/m
2 (adjusted meanSE
difference=2.401.10 kg; p=0.0324).
Discussion
Whereas the effects of TZD on lipids are well known, the
effects of insulin on lipids are not generally appreciated;
in fact, insulin therapy has been hypothesized to have
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Baseline LDL-C (mg/dL)
Quartile 1 2 3 4
Mean 72.1 101.7 121.7 160.6
Range 20.85-89.96 90.73-111.97 112.74-131.76 132.82-302.70
Baseline HDL-C (mg/dL) 
Quartile 1 2 3 4
Mean 32.7 39.8 45.5 57.0
Range 10.81-37.07 37.84-42.08 42.86-49.03 49.81-79.92
Baseline Non–HDL-C (mg/dL) 
Quartile   1  2  3  4 
Mean 107.9  139.6  165.2  215.1 
Range 51.74-127.80  128.57-151.73  151.74-180.69  181.46-396.53 
Baseline total cholesterol (mg/dL) 
Quartile   1  2  3  4 
Mean 148.6  182.3  209.1  259.2 
Range 106.95-168.73  169.88-194.59  195.75-223.55  224.71-475.29 
Baseline triglycerides (mg/dL) 
Quartile    1  2 3 4 
Mean  97.6  157.5 228.6 513.3 
Range 51.33-130.97  131.86-184.96  185.84-279.65  280.53-3418.58
Baseline free fatty acids (mg/dL) 
Quartile 1 2 3 4
Mean 31.6 48.4 65.3 100.1
Range 8.8-35.4 44.2-53.1 61.9-70.8 79.6-274.3
Figure 1. Changes in plasma lipid levels by treatment and baseline lipid quartile. (A) Low-density lipoprotein cholesterol (LDL-C); (B)
high-density lipoprotein cholesterol (HDL-C); (C) non-high-density lipoprotein cholesterol (non-HDL-C); (D) total cholesterol; (E)
triglycerides; (F) free fatty acids
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betes [8–10]. Our analysis shows that insulin glargine
treatment results in greater improvement in lipid levels
and more patients reaching the ADA/AHA recom-
mended lipid goals compared with pooled TZD treat-
ment in combination with metformin with or without
sulphonylureas. The beneﬁcial effects of insulin glar-
gine are greater in patients on lipid-lowering therapy.
Generally, the lipid beneﬁts of insulin glargine are
comparable with those of pioglitazone and better than
those of rosiglitazone. Reductions in A1C and FPG and
achievement of A1C ≤7.0% are greater than those
observed with pooled TZD treatment, especially for less
obese patients. As expected, hypoglycaemia was more
common among patients treated with insulin glargine
than among those treated with a TZD, but episodes of
severe hypoglycaemia were low in both treatment
groups.
Previous studies have shown an improvement in lipid
proﬁles of diabetic patients treated with insulin [17,22,23].
Treatment with 70% NPH insulin/30% regular insulin has
been shown to reduce TC and TGs in patients with type 2
diabetes [17]. Twenty-four weeks of insulin glargine with
standard oral anti-diabetic drug therapy decreases TC,
non-HDL-C, and TGs [15]. Insulin glargine or NPH insulin
combined with metformin results in a 27% to 29% decrease
in TGs and a 5% to 6% increase in HDL-C [18]. The current
analysis extends the information in the literature regarding
the effects of insulin glargine on all lipid parameters, as well
as the lipid ratios and lipid goals achieved in patients with
type 2 diabetes.
The effect of TZDs on lipids in this analysis is generally
consistent with previous reports on TZDs in patients with
type 2 diabetes. In a meta-analysis and in previous
studies, pioglitazone has been shown to reduce TGs
and LDL-C/HDL-C and increase HDL-C levels [24,25].
Rosiglitazone improves HDL-C; however, its effects on
LDL-C and TC are variable [26]. In a prospective ran-
domized clinical study comparing pioglitazone and
rosiglitazone in the treatment of patients with type 2
diabetes and dyslipidaemia, signiﬁcantly better outcomes
in TG, HDL-C, and LDL-C levels were reported for
pioglitazone than for rosiglitazone [27].
Given the evidence that statins improve clinical out-
comes and the large number of patients with elevated
LDL-C, non-HDL-C, and TGs at baseline, it was surprising
Table 4. Predictors of change in plasma lipid levels per stepwise regression analysis
Outcome Covariate Variance explained (%) p value
LDL-C LDL-C at baseline 28.47 <0.0001
HDL-C at baseline 2.10 0.0008
Concomitant statin/ﬁbrate use: no versus yes 1.83 0.0003
Treatment group: TZD versus insulin glargine 1.54 0.0008
Study: rosiglitazone versus pioglitazone 1.49 0.0032
Race: nonwhite versus white 0.61 0.0281
Sex: female versus male 0.43 0.0789
HDL-C Treatment group: TZD versus insulin glargine 6.09 <0.0001
Background use of both SU and metformin: no versus yes 4.60 0.0005
HDL-C at baseline 3.00 <0.0001
Sex: female versus male 1.59 0.0025
Background SU: no versus yes 0.56 0.0458
Age (years) 0.47 0.0188
Race: nonwhite versus white 0.52 0.0898
Non-HDL-C Total cholesterol at baseline 25.28 <0.0001
Study: rosiglitazone versus pioglitazone 3.36 <0.0001
Treatment group: TZD versus insulin glargine 2.64 <0.0001
Concomitant statin/ﬁbrate use: no versus yes 1.83 0.0002
Race: nonwhite versus white 1.22 0.0036
Total cholesterol Total cholesterol at baseline 26.71 <0.0001
Treatment group: TZD versus insulin glargine 4.31 <0.0001
Study: rosiglitazone versus pioglitazone 1.91 0.0014
Concomitant statin/ﬁbrate use: no versus yes 1.57 0.0005
Race: nonwhite versus white 1.05 0.0186
HDL-C at baseline 0.44 0.0751
Triglycerides Triglyceride at baseline 28.61 <0.0001
Study: rosiglitazone versus pioglitazone 3.83 <0.0001
HDL-C at baseline 2.40 0.0001
Race: nonwhite versus white 1.15 0.0036
Treatment group: TZD versus insulin glargine 0.76 0.0200
Concomitant statin/ﬁbrate use: no versus yes 0.47 0.0631
FFA FFA at baseline 50.93 <0.0001
A1C at baseline 1.18 0.0092
Diastolic blood pressure at baseline 0.76 0.0045
Study: rosiglitazone versus pioglitazone 0.78 0.0048
Sex: female versus male 0.48 0.0226
Treatment group: TZD versus insulin glargine 0.35 0.0610
Note: FFA, free fatty acid; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-
density lipoprotein cholesterol; SU, sulphonylurea; TZD, thiazolidinedione.
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lowering therapy. It is of interest that insulin glargine
produced greater improvement in lipid levels in patients
on statins or ﬁbrates, and a greater number of patients
on insulin glargine attained the ADA/AHA goals for LDL-
C, non-HDL-C, and TGs in this study. It is encouraging
that the greatest reduction in LDL-C occurred in patients
with the highest baseline levels. However, the ﬁnding of
increased LDL-C among patients in the lower baseline
quartiles reinforces the importance of monitoring patients
with elevated risk for cardiovascular disease and provid-
ing lipid-lowering therapy when appropriate.
Insulin regulates FFA, TG, and lipoprotein particle
metabolism through a variety of mechanisms, which
may account for the observed beneﬁcial lipid effects of in-
sulin glargine in this analysis. Insulin suppresses lipolysis,
preventing the release of FFAs from adipose tissue [28],
and increases the plasma clearance of FFAs [29]; these
effects result in a reduction of available substrate for
hepatic TG production [28]. Insulin also suppresses the
hepatocyte production of TGs and very low density
lipoproteins in vitro [30,31] and in vivo [29,32]. More-
over, insulin is a potent activator of lipoprotein lipase,
which enhances the catabolism of TG-rich lipoproteins
[28]. A signiﬁcant decrease in hepatic lipase activity also
has been observed following insulin therapy, which may
reduce the production of highly atherogenic small dense
LDL particles [23]. Insulin may promote LDL-C clearance
by enhancing LDL degradation [33,34]. Finally, insulin
regulates HDL particle synthesis through induction of
apolipoprotein A-1 gene expression in the liver [35].
Hyperglycaemia and dyslipidaemia are associated with
an increased risk of cardiovascular events in patients with
type 2 diabetes [36,37]. Our analysis suggests that insulin
has beneﬁcial effects on lipids and glucose in patients with
type 2 diabetes. The clinical impact of this observation on
cardiovascular risk reduction will be addressed speciﬁ-
cally in the ORIGIN (Outcome Reduction with Initial
Glargine Intervention) trial. This randomized con-
trolled study was designed to evaluate the effects of
insulin glargine on cardiovascular risk and mortality in
av a r i e t yo fd y s g l y c a e m i cp a t i ents (i.e. impaired fasting
glucose, impaired glucose tolerance, diabetes) who are
at high risk for a cardiovascular event [38]. Therefore,
the ﬁndings of this study will be applicable to a broad
spectrum of patients with glycaemic abnormalities [38].
The choice of antihyperglycaemics should be individu-
alized according to the patient’s medical history, disease
characteristics, comorbidities, baseline A1c, lifestyle, body
weight, and risk of adverse events. Insulin glargine might
be more appropriate for patients requiring a greater re-
duction in A1c, whereas TZD might be more appropriate
for patients with a history of severe hypoglycaemia. On
the basis of our study, either insulin glargine or pioglita-
zone can be chosen if additional beneﬁts on lipids are a
consideration for choosing an antihyperglycaemic agent.
Insulin glargine might be more appropriate, for instance,
in patients taking a lipid-lowering medication, in light of
the synergistic effects of statins and insulin glargine
observed in this study, whereas pioglitazone may be
preferred if HDL is very low. Either insulin glargine or
pioglitazone may be beneﬁcial in patients at risk for
cardiovascular disease.
Analysis limitations
This analysis pooled results from studies of rosiglitazone
and pioglitazone [19,20], which are known to have differ-
ent effects on lipid parameters [39,40]. The lipid results,
therefore, are presented separately for rosiglitazone and
pioglitazone. Glycaemic outcomes are presented only for
pooled TZD treatment because TZDs have similar glycaemic
effects [39,40]. Differences attributable to other anti-
diabetic agents cannot be evaluated, as participants in the
rosiglitazone study received both metformin and a
sulphonylurea [19] whereas participants in the pioglitazone
study received either one or the other [20]. However, TZD
use accounted for variability only in HDL-C in the lipid
regression models. Furthermore, doses of statin and ﬁbrate
medications were not held constant during treatment. The
possibility that potential dosage titrations of these lipid-
lowering medications contributed to the observed lipid
effects cannot be excluded. A future comparative study of in-
sulin glargine versus pioglitazone, with the addition of more
detailed lipid measurements, such as apolipoproteins and
small dense LDL particles, and with statin dose held constant
during the treatment period, would provide further insight
into the lipid-lowering effects of these two medications.
Safety
The higher frequency of episodes of hypoglycaemia with
insulin glargine and weight gain and peripheral oedema
with TZD in our analysis are consistent with the known side
effects of these agents. Episodes of severe hypoglycaemia
occurred in fewer than 3% of patients receiving either
treatment [19,20].
Conclusion
Treatment with insulin glargine showed beneﬁcial effects
on lipid parameters, which are generally comparable with
the effects of pioglitazone and more favourable than those
of rosiglitazone. Lipid improvement occurred within the
context of better glycaemic control attained with insulin
glargine. Insulin glargine treatment led to more hypogly-
caemia but less weight gain and oedema compared with
TZD treatment. Both insulin glargine and TZDs promoted
changes in lipid proﬁle; however, there were some speciﬁc
qualitative and quantitative differences depending on the
agent used to lower blood glucose. These ﬁndings suggest
that favourable effects on plasma lipid proﬁles should be
considered among the advantages of treatment with insulin
glargine as they are for TZDs.
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